264 related articles for article (PubMed ID: 22576016)
1. CD163 expression is increased in the involved skin and sera of patients with systemic lupus erythematosus.
Nakayama W; Jinnin M; Makino K; Kajihara I; Makino T; Fukushima S; Sakai K; Inoue Y; Ihn H
Eur J Dermatol; 2012; 22(4):512-7. PubMed ID: 22576016
[TBL] [Abstract][Full Text] [Related]
2. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
3. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis.
Baeten D; Møller HJ; Delanghe J; Veys EM; Moestrup SK; De Keyser F
Arthritis Rheum; 2004 May; 50(5):1611-23. PubMed ID: 15146432
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of soluble CD163 as a biomarker for macrophage activation syndrome associated with systemic lupus erythematosus.
Nishino A; Katsumata Y; Kawasumi H; Hirahara S; Kawaguchi Y; Yamanaka H
Lupus; 2019 Jul; 28(8):986-994. PubMed ID: 31246559
[TBL] [Abstract][Full Text] [Related]
5. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis.
Bleesing J; Prada A; Siegel DM; Villanueva J; Olson J; Ilowite NT; Brunner HI; Griffin T; Graham TB; Sherry DD; Passo MH; Ramanan AV; Filipovich A; Grom AA
Arthritis Rheum; 2007 Mar; 56(3):965-71. PubMed ID: 17328073
[TBL] [Abstract][Full Text] [Related]
7. Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels.
Davis BH; Zarev PV
Cytometry B Clin Cytom; 2005 Jan; 63(1):16-22. PubMed ID: 15624200
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
9. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD.
Axelsson J; Møller HJ; Witasp A; Qureshi AR; Carrero JJ; Heimbürger O; Bárány P; Alvestrand A; Lindholm B; Moestrup SK; Stenvinkel P
Am J Kidney Dis; 2006 Dec; 48(6):916-25. PubMed ID: 17162146
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of soluble CD163 as a marker of inflammation in psoriasis.
Feighery C; Dunne J; Bingham EA; Feighery CF
Clin Exp Dermatol; 2011 Mar; 36(2):201-3. PubMed ID: 21323937
[TBL] [Abstract][Full Text] [Related]
11. Expression of soluble sCD163 in serum of psoriatic patients is modulated by Goeckerman therapy.
Kondelkova K; Krejsek J; Borska L; Fiala Z; Hamakova K; Andrys C
Allergol Immunopathol (Madr); 2013; 41(3):158-62. PubMed ID: 22765877
[TBL] [Abstract][Full Text] [Related]
12. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma.
Jones K; Vari F; Keane C; Crooks P; Nourse JP; Seymour LA; Gottlieb D; Ritchie D; Gill D; Gandhi MK
Clin Cancer Res; 2013 Feb; 19(3):731-42. PubMed ID: 23224400
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure.
Hiraoka A; Horiike N; Akbar SM; Michitaka K; Matsuyama T; Onji M
J Gastroenterol; 2005 Jan; 40(1):52-6. PubMed ID: 15692789
[TBL] [Abstract][Full Text] [Related]
14. Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma.
Andersen MN; Abildgaard N; Maniecki MB; Møller HJ; Andersen NF
Eur J Haematol; 2014 Jul; 93(1):41-7. PubMed ID: 24612259
[TBL] [Abstract][Full Text] [Related]
15. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
[TBL] [Abstract][Full Text] [Related]
16. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.
Moreno JA; Dejouvencel T; Labreuche J; Smadja DM; Dussiot M; Martin-Ventura JL; Egido J; Gaussem P; Emmerich J; Michel JB; Blanco-Colio LM; Meilhac O
Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1253-62. PubMed ID: 20299688
[TBL] [Abstract][Full Text] [Related]
17. Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease.
Møller HJ; de Fost M; Aerts H; Hollak C; Moestrup SK
Eur J Haematol; 2004 Feb; 72(2):135-9. PubMed ID: 14962251
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD163.
Møller HJ
Scand J Clin Lab Invest; 2012 Feb; 72(1):1-13. PubMed ID: 22060747
[TBL] [Abstract][Full Text] [Related]
19. Soluble CD163 is not increased in visceral fat and steatotic liver and is even suppressed by free fatty acids in vitro.
Bauer S; Weiss TS; Wiest R; Schacherer D; Hellerbrand C; Farkas S; Scherer MN; Ritter M; Schmitz G; Schäffler A; Buechler C
Exp Mol Pathol; 2011 Dec; 91(3):733-9. PubMed ID: 21839737
[TBL] [Abstract][Full Text] [Related]
20. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.
Møller HJ; Moestrup SK; Weis N; Wejse C; Nielsen H; Pedersen SS; Attermann J; Nexø E; Kronborg G
Crit Care Med; 2006 Oct; 34(10):2561-6. PubMed ID: 16915112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
